Resolving an inflammatory concept: The importance of inflammation and resolution in tendinopathy  by Dakin, Stephanie G. et al.
RR
i
S
R
A
R
R
1
A
K
T
I
T
P
I
R
C
l
d
C
0
hVeterinary Immunology and Immunopathology 158 (2014) 121–127
Contents lists available at ScienceDirect
Veterinary  Immunology  and  Immunopathology
j ourna l h omepa ge: www.elsev ier .com/ locate /vet imm
eview  Paper
esolving  an  inﬂammatory  concept:  The  importance  of
nﬂammation  and  resolution  in  tendinopathy
tephanie  G.  Dakin ∗, Jayesh  Dudhia,  Roger  K.W.  Smith
oyal Veterinary College, Department of Clinical Sciences and Services, North Mymms, Hatﬁeld, Hertfordshire AL9 7TA, United Kingdom
a  r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 28 October 2013
eceived in revised form
9 December 2013
ccepted 6 January 2014
eywords:
endon
njury
endinopathy
athogenesis
nﬂammation
a  b  s  t  r  a  c  t
Injuries  to the superﬁcial  digital  ﬂexor  tendon  (SDFT)  are  an important  cause  of  morbidity
and  mortality  in equine  athletes,  but the healing  response  is  poorly  understood.  One  impor-
tant drive  for  the  healing  of  connective  tissues  is the inﬂammatory  cascade,  but  the  role of
inﬂammation  in tendinopathy  has  been  contentious  in  the  literature.  This  article  reviews
the  processes  involved  in the healing  of  tendon  injuries  in  natural  disease  and  experimental
models.  The  importance  of inﬂammatory  processes  known  to be active  in  tendon  disease
is discussed  with  particular  focus  on recent  ﬁndings  related  speciﬁcally  to  the horse.
Whilst  inﬂammation  is necessary  for debridement  after  injury,  persistent  inﬂammation
is  thought  to drive  ﬁbrosis,  a perceived  adverse  consequence  of  tendon  healing.  There-
fore  the  ability  to resolve  inﬂammation  by the  resident  cell  populations  in tendons  at  an
appropriate  time  would  be crucial  for successful  outcome.  This review  summarises  new
evidence  for  the  importance  of resolution  of  inﬂammation  after tendon  injury.  Given  thatesolution many anti-inﬂammatory  drugs  suppress  both  inﬂammatory  and  resolving  components  of
the  inﬂammatory  response,  prolonged  use  of  these  drugs  may  be  contraindicated  as  a ther-
apeutic  approach.  We  propose  that  these ﬁndings  have  profound  implications  not  only  for
current  treatment  strategies  but  also  for the possibility  of  developing  novel  therapeutic
approaches  involving  modulation  of  the  inﬂammatory  process.
©  2014  Elsevier  B.V.  All  rights  reserved.
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stain positively for pro-inﬂammatory cytokines IL-1, IL-
1, TNF- and IFN- which were not found in normal
tendons (Hosaka et al., 2002). Hence in conjunction with
Box 1: Terminology
The terms below are used commonly in a variety of
clinical scenarios but have not been well deﬁned. For
the purposes of this review, we have attempted to clar-
ify what would be considered the most appropriate use
of these terms.
‘Tendinopathy’ is used to describe disorders affect-
ing tendons, including tendon rupture and chronic
pain. This term does not assume any knowledge about
the underlying pathology.
‘Tendonitis’ is used to describe a painful tendon
and implies that tendon injury is accompanied by an
inﬂammatory response.
‘Tendinosis’ is used to describe a painful tendon and
implies that tendon injury develops as a consequence
of a degenerative process and implies absence of
inﬂammation.
‘Tendon disease’ implies that injury develops as
a consequence of repetitive cyclic loading and the
effects of ageing resulting in cumulative micro-
damage. Often exacerbated by overstrain injury, the
most common manifestation in the horse is a central
core lesion.122 S.G. Dakin et al. / Veterinary Immunolo
1. Introduction
Pathologic changes in tendons due to repetitive use
are a signiﬁcant cause of morbidity in athletic humans
and horses (Avella et al., 2009; Kujala et al., 2005; Thorpe
et al., 2010). The importance of inﬂammation in both the
pathogenesis of tendon injury and the healing process has
been contentious in recent years and is poorly understood.
Equine clinicians are familiar with the clinical signs of
inﬂammation immediately after a tendon injury occurs, but
these signs are not so evident during the chronic phase
of injury. Overstrain injury in humans is generally con-
sidered to result from a primarily degenerative condition
where clinical signs of inﬂammation and invading inﬂam-
matory cells are rarely observed (Alfredson and Lorentzon,
2002; Astrom and Rausing, 1995; Jarvinen et al., 1997;
Jozsa et al., 1990; Kannus and Jozsa, 1991; Webbon, 1978).
However, this lack of perceived clinical inﬂammation may
be attributable to factors such as the later presentation
of human patients, frequently with recurrent injury and
the availability of tissues for analysis at different times
after injury. Furthermore, the absence of clinically evident
inﬂammation does not preclude an integral role for inﬂam-
matory mediators during the pathogenesis and healing
of tendon injuries at a cellular level. Current controversy
regarding the role of inﬂammation in tendon injury and
healing is similar to that previously debated in joint disease.
Use of the term ‘arthritis’ with its emphasis on inﬂam-
mation, has generally replaced the term ‘arthrosis’ when
referring to a wide variety of joint disease conditions (Attur
et al., 2002). This change in terminology reﬂects the fact
that inﬂammatory cytokines have recently been shown to
play a pivotal role in the development of joint disease even
when clinical signs of inﬂammation may  not be detected.
Terminology commonly used to refer to tendon pathology
is further described in Box 1.
Several laboratory animal models have been used to
investigate tendon injury; however, these induced injury
models do not accurately reproduce the naturally occur-
ring conditions that are detected in human and equine
patients (Lui et al., 2011). Horses, on the other hand suf-
fer a high frequency of clinical overstrain injury involving
a wide spectrum of tendons and ligaments. Therefore the
horse presents an attractive large animal model not only
for equine related studies but also as a relevant model of
human injury due to the shared characteristics of aging
phenotypes (Dudhia et al., 2007; Strocchi et al., 1991), elas-
tic energy storing function common to the weight-bearing
tendons of both species (Ker et al., 2000; Wilson et al., 2001)
and injury induced by natural athletic activity. Equine
tendon healing processes are traditionally classiﬁed into
three distinct but overlapping phases in naturally occurring
injury; the acute inﬂammatory phase occurs immediately
after the initial trauma lasting only a few days, followed
by the sub-acute reparative phase (peaking at 3–6 weeks
but lasting several months and chronic remodelling phase
(>3 months after injury) (Dowling et al., 2000). Whilst
this temporally coordinated but overlapping sequence of
events describes very well the clinical progression of SDFT
lesions and other injuries such as some suspensory branch
desmopathies in the horse, injuries to the human Achillesmunopathology 158 (2014) 121–127
tendon manifest differently with less well deﬁned phases
characterised by persistent pain and ‘failed healing’ (Longo
et al., 2009). These clinical descriptions of the healing
phases suggest that inﬂammation drives acute and chronic
phases of injury. However recent insights into the under-
lying molecular events suggest that some components of
the inﬂammatory cascade are necessary for resolution of
injury. This review will discuss the inﬂammatory mediators
relevant to tendon disease and illustrate that in addition to
pro-inﬂammatory roles, inﬂammation triggers important
resolution processes, which can potentially be harnessed
for beneﬁcial therapeutic effect.
2. Inﬂammation related mediators in tendon health
and disease
2.1. Cytokines in tendinopathy
Cytokines are small proteins with the ability to inﬂu-
ence the biological activities of cells and operate in an
autocrine/paracrine manner. They are highly potent and
exert their effects at picomolar concentrations. The inter-
action between a cytokine and its receptor triggers a series
of intracellular signalling events culminating in a physio-
logical response (Evans, 1999). Cytokines are reported to
have important roles in tendon and ligament homeostasis
by regulating cellular differentiation and activity (Evans,
1999; Lin et al., 2006; Molloy et al., 2003) and the syn-
thesis of tendon matrix (Millar et al., 2009; Riley, 2005;
Sun et al., 2008). However, samples of injured equine SDFT‘Tendon injury’  encompassing tendon disease but
also occurs as a consequence of traumatic injury when
the tendon is lacerated after cutaneous injury.
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heir proposed homeostatic roles, cytokines are also poten-
ial contributors to the development of tendinopathy.
In addition to the study of natural tendon disease,
odent models of induced tendon injury and in vitro
ell/tissue culture studies have been utilised to inves-
igate the roles of cytokines in tendinopathy. Treadmill
unning of rats to simulate tendon overuse showed up-
egulation of inﬂammation-related genes IL-11, IL-15, IL-6,
NF- (Millar et al., 2009). The fatigue loading of rat patel-
ar tendons produced structural changes accompanied by
ncreased expression of both MMP-13 and IL-1  (Sun
t al., 2008). Furthermore, both repetitive cyclical stretch-
ng of tendon ﬁbroblasts in vitro and stimulation with IL-1
nduced MMP  production and expression of COX-2 and
GE2 (Archambault et al., 2002; Tsuzaki et al., 2003; Yang
t al., 2005). Not only are cytokines associated with the
nset of injury, the macrophages releasing these cytokines
re potentially important for effective debridement and
ubsequent healing of the injured tendon. For example,
ealing was shown to be inferior in a surgical model of
atellar tendon injury in IL-6 knockout mice, even though
L-6 has both pro and anti-inﬂammatory effects (Lin et al.,
006).
.2. Prostaglandin lipid mediators in tendinopathy
Prostaglandins also have potentially important roles
n tendon health and disease. Prostaglandins are syn-
hesised from arachadonic acid by COX-1 and COX-2.
rachadonic acid is in turn derived from the cell mem-
rane phospholipid bilayer by the activity of phospholipase
nzymes in response to trauma, cytokines and growth fac-
ors (Funk, 2001). Prostaglandins act in an autocrine or
aracrine fashion at nanomolar concentrations (Stables
nd Gilroy, 2011). There are 3 series of prostaglandins;
he 1 series prostaglandins give rise to PGE1 and PGF1,
 series prostaglandins include PGD2, PGE2 and PGF2 and
he 3 series prostaglandins PGE3 and PGF3 (Abayasekara
nd Wathes, 1999). Prostaglandins of the 1 and 3 series
re considered to be less biologically active than those of
he 2 series (Irvine, 1982; Lands, 1992). These lipid medi-
tors exert their biological effects by binding to a series
f receptors present on the surface of cell membranes.
ultiple receptor subtypes have been identiﬁed in mice
nd humans, including the prostaglandin D receptors DP1,
P2 and the prostaglandin F receptor FP. A series of four
rostaglandin E (EP) receptor subtypes are responsible for
ediating the downstream effects of PGE2, which include
P1, EP2, EP3 and EP4.
Constitutive prostaglandin production is a prerequisite
or normal physiologic processes in many tissues and cells
f the body including bone remodelling, modiﬁcation of
lood ﬂow (both vasoconstriction or vasodilation), vascular
ermeability, smooth muscle tone and platelet aggregation
Dunn, 1987; Graham et al., 2009; Petrucci et al., 2011; Saito
t al., 1988; Williams, 1979). Prostaglandin production
ppears to be a normal physiologic response of tendon cells
o repetitive motion. For example, PGE2 levels increased
n the peri-tendinous Achilles region of healthy exercising
umans (Langberg et al., 1999) and in murine patellar and
chilles tendons following treadmill exercise (Zhang andmunopathology 158 (2014) 121–127 123
Wang, 2010). These observations are supported by in vitro
experiments whereby tendon ﬁbroblasts in culture release
PGE2 in response to repetitive cyclic strain (Almekinders
et al., 1993, 1995; Wang et al., 2004).
In addition to constitutive production, prostaglandins
are produced in response to injury (Tilley et al., 2001). PGE2
is released by tendon ﬁbroblasts in vitro in response to stim-
ulation with IL-1 in a COX-2 dependent manner (Tsuzaki
et al., 2003; Yang et al., 2005) and the inducible terminal
synthase of PGE2 (microsomal prostaglandin E synthase-1,
mPGES-1) is also up-regulated by IL-1 (Jakobsson et al.,
1999; Kojima et al., 2002). The role of prostaglandins in
tendinopathy is complex and diverse with evidence sup-
porting both deleterious and beneﬁcial effects. Deleterious
effects were observed after peri-tendinous injection of
PGE1 into the rat Achilles tendon leading to increased ten-
don cross sectional area and degenerative changes similar
to those observed in human tendinopathy after 5 weeks
(Sullo et al., 2001). Similarly, repeated intratendinous injec-
tion of 500 ng PGE2 into rabbit patellar tendons culminated
in degenerative changes such as focal hyper cellularity,
disorganised tissue architecture and reduced collagen ﬁb-
ril diameter compared with control tendons (Khan et al.,
2005). This may  be effectuated via the prostaglandin EP4
receptor that appears to mediate the degradative effects
of IL-1 induced prostaglandins (Thampatty et al., 2007). In
addition to IL-1, PGE2 potentiates ECM catabolism in carti-
lage, periodontal ligament (Attur et al., 2008; Ruwanpura
et al., 2004) and tendon via increased expression of MMP-1
and MMP-3 mRNA (Thampatty et al., 2007; Tsuzaki et al.,
2003; Yang et al., 2005) and proteins (Tsuzaki et al., 2003).
However, evidence also exists to support a positive
role of PGE2 in tendon healing. Peri-tendinous injections
of 800 ng PGE2 into the rat patellar tendon improved
tendon mechanical properties compared to non-treated
controls or saline-injected tendons (Ferry et al., 2012).
The role of PGE2 in equine tendons has not been exten-
sively studied, although we have shown that higher doses
of PGE2 countered the catabolic effects of IL-1 in an
in vitro model of equine tendon inﬂammation (Dakin
et al., 2012a). NSAIDs inhibit prostaglandin production
and are widely used pharmacological agents for the treat-
ment of inﬂammatory diseases and to alleviate the pain
associated with tendinopathy. Despite evidence suggest-
ing inﬂammation also having detrimental effects on the
healing process of connective tissues, non-speciﬁc block-
ade of the inﬂammatory response may  not necessarily
be beneﬁcial to the healing process (Magra and Maffulli,
2006; Marsolais et al., 2003). Inhibition of prostaglandin
synthesis in tendon ﬁbroblasts undergoing cyclical stretch
in vitro results in a compensatory elevation in levels of the
pro-inﬂammatory leukotriene B4, potentially exacerbating
inﬂammation (Li et al., 2004). Studies have revealed the
potential for COX inhibitors to impair healing of tendons
(Cohen et al., 2006; Ferry et al., 2007) and reduce exercise-
induced increases in collagen synthesis in the human
patellar tendon (Christensen et al., 2011). Moreover PGE2
generated during inﬂammation, activates specialised pro-
resolving lipid mediators such as lipoxins and resolvins,
which are essential in restoring tissue homeostasis after
inﬂammation or injury (Levy et al., 2001; Serhan et al.,
gy and Im124 S.G. Dakin et al. / Veterinary Immunolo
2000a, 2004). Hence ‘switching off’ prostaglandins is likely
to have a negative impact upon the body’s endogenous
mechanisms to regulate inﬂammation (Gilroy et al., 1999;
Serhan, 2005).
Prostaglandins also exhibit immuno-modulatory prop-
erties, for example PGE2 down-regulates the inﬂammatory
response via inhibiting production of pro-inﬂammatory IL-
12 whilst stimulating production of the anti-inﬂammatory
cytokine IL-10 (van der Pouw Kraan et al., 1995). Hence
prostaglandins such as PGE2 exhibit double-edged sword
properties in terms of their perceived beneﬁcial and detri-
mental effects on tendons. This may  be inﬂuenced by the
dose of PGE2 and experimental model used, however the
concept of maintaining a balance to ensure regulation of
prostaglandin production in tendons is likely to be of phys-
iological importance.
2.3. Inﬂammation triggers resolution
An intriguing dimension to the physiology of inﬂam-
mation is the identiﬁcation of specialised pro-resolving
mediators (SPM) encompassing lipoxins such as lipoxin
A4 (LXA4) (Serhan et al., 1984) acting upon the resolv-
ing receptor FPR2/ALX (Ye et al., 2009) and more recently,
the resolvins and maresins (Serhan et al., 2002, 2009).
FPR2/ALX is expressed by monocytes and macrophages
(Yang et al., 2001) and is central in controlling the duration
and magnitude of the inﬂammatory response, providing
endogenous stop signals for inﬂammation (Serhan et al.,
2000b). Resolution pathways are programmed responses
activated during inﬂammation, resulting in a switch in
lipid mediators from the dominance of prostaglandins to
the lipoxins to promote resolution of inﬂammation and
the return of tissues to their normal homeostatic state
(Levy et al., 2001; Serhan et al., 2008, 1984, 2000b). Impor-
tantly, resolution has been shown to be an active and
highly regulated physiological process (Serhan et al., 2007;
Serhan and Chiang, 2008) rather than simple passive cessa-
tion of inﬂammation as previously thought. Key events in
resolution of inﬂammation include phagocytosis of apop-
totic cells, modiﬁcation of inﬂammatory cell inﬁltration to
the inﬂamed site and modulation of vascular permeabil-
ity (Serhan et al., 2007). However, whilst resolution is well
studied in experimental murine models of inﬂammation,
there is limited information documenting this process in
naturally diseased connective tissues and resolution has
only recently been identiﬁed in injured equine tendons
(Dakin et al., 2012a,b).
3. Recent developments on the role of
inﬂammation in equine tendinopathy: implications
for current clinical practice
There is little published information that has addressed
the role of inﬂammation in equine tendon disease. A per-
sistent inﬂammatory stimulus with sustained production
of growth factors, proteolytic enzymes and cytokines is a
common feature of ﬁbrotic diseases, stimulating the depo-
sition of connective tissue elements that are detrimental
to normal tissue architecture (Wynn, 2004). Fibrosis is
the ﬁnal common pathogenic process for many forms ofmunopathology 158 (2014) 121–127
chronic inﬂammatory disease (Leask et al., 2002). Although
the deposition of scar tissue is an integral component of the
healing response, the altered composition of the tendon
ECM compromises the structural and functional proper-
ties of tendons and potentially contributes towards the
high risk of re-injury (Crevier-Denoix et al., 1997; Dakin
et al., 2011). Through the study of natural tendon injury
in the horse, we  have demonstrated that aberrations in
the enzymes regulating PGE2 metabolism occur soon after
injury (Dakin et al., 2012a). In addition, components of
inﬂammation have also been shown to be highly active at
this stage, demonstrated by the presence of M1 polarised
macrophages (M) (Dakin et al., 2012b), which release pro-
inﬂammatory mediators such as IL-1 and PGE2. During
the later phase of tendon healing, the M2M phenotype
predominates (releasing anti-inﬂammatory cytokines) and
we have proposed that these cells are actively surveying the
healing tendon for ‘stress signals’ to protect this susceptible
region from re-injury.
The practice of using steroids and non-steroidal anti-
inﬂammatory drugs (NSAIDs) to relieve pain associated
with tendon injury is controversial. Whilst appropriate
short term systemic use of these drugs is unlikely to
be associated with deleterious patient side effects, pro-
longed use of NSAIDs or intratendinous injection of steroid
preparations are associated with adverse effects on ten-
don mechanical properties (Virchenko et al., 2004) and
propensity for rupture (Shrier et al., 1996), respectively.
Furthermore, adverse systemic effects of NSAIDs also
include gastrointestinal ulceration (Videla and Andrews,
2009), which occurs due to disruption of normal homeo-
static mechanisms involving prostaglandin synthesis.
Whilst the inﬂammatory component of tendinopathy has
received much attention, the processes concerned with
resolution of tendon inﬂammation have been neglected
from a therapeutic perspective. Improved understand-
ing of inﬂammation is crucial to the development of
novel anti-inﬂammatory agents that preserve the ben-
eﬁcial, yet remove the detrimental components of the
cascade. Although the ﬁeld of resolving inﬂammation is
relatively new, understanding of pro-resolution processes
is rapidly evolving using murine models of experimen-
tally induced inﬂammation (Navarro-Xavier et al., 2010;
Rajakariar et al., 2008). Inhibiting inﬂammation has been
shown to ‘switch off’ the activation of key inﬂammation-
resolving mechanisms (Gilroy et al., 1999). Harnessing
the potential of pro-resolving mediators represents a
new approach to managing inﬂammatory diseases in the
future. Pro-resolving pathways have not been widely
studied in injured tendons, although we  have demon-
strated increased expression of the pro-resolving receptor
FPR2/ALX (Dakin et al., 2012b) and the switch from
pro-inﬂammatory prostaglandins to the production of pro-
resolving lipids such as LXA4 during the early stage of
tendon injury (Dakin et al., 2012a). However, it is hypothe-
sised that this resolving response is somehow dysregulated
or of insufﬁcient duration or magnitude, as tendon inﬂam-
mation is not adequately ‘switched off’ (Dakin et al., 2012b).
This favours the development of chronic inﬂammation and
the formation of a ﬁbrogenic repair scar (Fig. 1). In support
of this concept, expression of the pro-resolving receptor
S.G. Dakin et al. / Veterinary Immunology and Immunopathology 158 (2014) 121–127 125
Fig. 1. Schematic to propose the relationship between inﬂammation and resolution in the development of tendon injury. (A) In early stage injury, inﬂam-
mation triggers a tendon resolution response, which appears to be transient and reduces with age and time after injury. During the later stages of healing
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echronic  injury) we  propose that insufﬁcient or dysregulated resolution
ealing and re-injury. (B) To improve the healing response of tendon, a p
nhancing the tendons resolution response.
PR2/ALX (a critical component in mediating pro-resolving
echanisms) has been shown to reduce with time after
endon injury and with ageing (Dakin et al., 2012a). This
s likely to have implications for sustaining chronic tendon
njury if acute inﬂammation is insufﬁciently resolved, and
n the development of re-injury with age because the ability
o resolve tendon inﬂammation diminishes with ageing.
. Conclusions
Selectively managing tendon injuries according to their
isease stage is likely to be an important aspect determin-
ng the success of therapy. Future therapeutic management
f early stage tendon injury may  require addressing both
ides of the inﬂammation equation, whereby inﬂamma-
ory processes can be modulated to prevent inappropriate
r prolonged ECM degradation, whilst simultaneously
nhancing pro-resolving processes. In the chronic stage
f tendon disease it may  be more appropriate to avoid
he use of NSAIDs due to their perceived adverse effects
n collagen synthesis (Christensen et al., 2011). Instead,
reatment of chronic tendon injury could focus on pro-
oting pro-resolution processes by guiding chronically
nﬂamed tissues into a resolving pathway. This may  be
ccomplished by addressing novel therapeutic targets such
s pro-resolving lipids or proteins (Gilroy, 2010; Gilroy
t al., 2004; Morris et al., 2010), which may  be beneﬁcial in
educing the propensities for ﬁbrotic tendon healing and
e-injury.
The capacity to prevent tendon injury remains the
ltimate goal; however this is currently precluded by
ur inability to accurately identify sub-clinical injuries
n vivo. Sub-clinical injuries are attributable to the effects
f exercise and have been identiﬁed during post mortem
xamination of equine SDFTs (Birch et al., 1998; Smith et al.,low-level inﬂammation to persist, increasing the propensity for ﬁbrotic
therapeutic strategy is to moderate inﬂammation whilst simultaneously
1999). Future research should aim to identify parameters
that determine the inﬂammatory status of injured tendons
in vivo. This encompasses the development of biomark-
ers of tendon injury (Dakin et al., 2014; Jackson et al.,
2003; Smith and Heinegard, 2000), which may  facilitate
identiﬁcation of sub-clinical injuries prior to the onset of
overt clinical disease. This review highlights the impor-
tance of a ﬁnely balanced inﬂammatory response in tendon
healing. The recent identiﬁcation of pro-resolving media-
tors in healing equine tendons provides novel therapeutic
opportunities in the quest for effective prevention and
treatment.
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